BRIEF published on 11/21/2025 at 11:25, 10 months 18 days ago Crossing of thresholds by Samsara BioCapital at INVENTIVA Voting Rights Capital Increase Threshold Crossing Inventiva Samsara BioCapital
PRESS RELEASE published on 11/13/2025 at 15:21, 10 months 26 days ago Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
BRIEF published on 11/13/2025 at 08:45, 10 months 26 days ago Inventiva Announces Temporary Trading Halt on Euronext Paris Euronext Paris Nasdaq Trading Halt Inventiva ADS Offering
PRESS RELEASE published on 11/13/2025 at 08:40, 10 months 26 days ago Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris Inventiva temporarily halts trading of ordinary shares on Euronext Paris for public offering preparation, with expected resumption by end of day. Company focuses on MASH treatment research Euronext Paris Trading Halt Public Offering Inventiva MASH Treatment
BRIEF published on 10/14/2025 at 22:05, 11 months 25 days ago Inventiva Launches New ATM Program to Raise $100 Million Biopharmaceutical SEC Filing Inventiva Lanifibranor ATM Program
PRESS RELEASE published on 10/14/2025 at 22:00, 11 months 26 days ago Inventiva Announces the Implementation of a New ATM Program Inventiva implements new ATM program, files Registration Statement with the SEC for up to $100 million aggregate gross sales proceeds. Proceeds to fund research and development, working capital, and corporate purposes Biopharmaceutical SEC Registration Statement Inventiva ATM Program
BRIEF published on 10/07/2025 at 22:05, 1 year ago Inventiva at Liver Meeting 2025: Key Presentations on Lanifibranor Digital Pathology Inventiva MASH Lanifibranor Liver Meeting 2025
PRESS RELEASE published on 10/07/2025 at 22:00, 1 year ago Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 Inventiva to present multiple abstracts at AASLD The Liver Meeting® 2025 showcasing digital pathology data and therapeutic benefits of lanifibranor in MASH treatment. Visit booth #745 for more Digital Pathology Inventiva MASH Lanifibranor AASLD The Liver Meeting
BRIEF published on 10/01/2025 at 08:35, 1 year ago Andrew Obenshain Appointed as CEO of Inventiva Leadership Transition Drug Development Inventiva MASH Treatment Andrew Obenshain
PRESS RELEASE published on 10/01/2025 at 08:30, 1 year ago Inventiva Appoints Andrew Obenshain as Chief Executive Officer Inventiva appoints Andrew Obenshain as Chief Executive Officer, succeeding Frédéric Cren, to lead company's growth and prepare for potential commercialization in the United States Chief Executive Officer Inventiva MASH Frédéric Cren Andrew Obenshain
Published on 10/09/2026 at 14:00, 8 hours 4 minutes ago Stillwater Critical Minerals Upgrades to OTCQX Best Market, Expanding U.S. Market Presence
Published on 10/09/2026 at 14:00, 8 hours 4 minutes ago Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Published on 10/09/2026 at 13:23, 8 hours 41 minutes ago SLAM Exploration Announces Leadership Transition and Appointment of Jimmy Gravel as President and CEO
Published on 10/09/2026 at 13:00, 9 hours 4 minutes ago Horizon Aircraft Reports Fiscal 2027 First Quarter Results and Advances Full-Scale Cavorite X7 Development
Published on 10/09/2026 at 13:00, 9 hours 4 minutes ago Nepra Foods Launches Flagship PROPASTA Brand on Amazon
Published on 10/09/2026 at 21:24, 39 minutes ago Branicks Group AG: Extraordinary General Meeting does not approve all items on the agenda
Published on 10/09/2026 at 21:17, 46 minutes ago EQS-Adhoc: Branicks Group AG: Agenda topic four at extraordinary general meeting rejected
Published on 10/09/2026 at 19:22, 2 hours 42 minutes ago EQS-Adhoc: elumeo SE switches financial reporting to comply with the German Commercial Code (HGB) and refines forecast for 2026
Published on 10/09/2026 at 18:00, 4 hours 4 minutes ago ARVERNE GROUP: Arverne reaches a major milestone: Europe recognizes the Lithium de France Project as a pillar of its industrial sovereignty
Published on 10/09/2026 at 19:27, 2 hours 37 minutes ago Disclosure of transactions in own shares from October 1 to October 9, 2026
Published on 10/08/2026 at 18:30, 1 day 3 hours ago Cegedim: Release of its 2026 Interim Financial Report
Published on 10/08/2026 at 18:00, 1 day 4 hours ago Launch of LINK, the next generation of THIN: Clinityx’s first European Health Data Warehouse, approved by the French Data Protection Authority for 10 years
Published on 10/08/2026 at 17:45, 1 day 4 hours ago Carrefour announces a real estate sale and leaseback transaction involving 35 stores in France and Spain
